Navigation Links
Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
Date:2/14/2008

p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients' baseline prognostic factors. However, the CD54 upregulation ratio appeared to be an independent predictor of survival in patients who received PROVENGE, as the correlation remained strong even after adjusting for baseline prognostic factors (p=0.022).

"We have been able to show a correlation between patient survival and a measure of the cumulative potency of PROVENGE; such a correlation between product potency and clinical outcome has not been previously demonstrated with an active immunotherapy," said Mark Frohlich, MD, chief medical officer of Dendreon. "These data provide further evidence that sipuleucel-T is actively engaging the immune system in a clinically meaningful way that prolongs patient survival."

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 218,890 new cases expected to be diagnosed in 2007, and more than 27,000 men expected to die this year from the disease. Currently, there are limited treatment options for men with advanced, metastatic prostate cancer.

About Active Cellular Immunotherapy with PROVENGE

PROVENGE may represent the first product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. In clinical studies, patients typically received three doses of PROVENGE over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system t
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... MC Medical, a subsidiary of Mitsubishi Corporation (MCM), and Minimally ... medical device company, have formally agreed to an exclusive ... in Japan . It is anticipated that ... in the latter half of 2015. ... in endoscopic surgery market in Japan . ...
(Date:8/22/2014)... , Aug. 22, 2014  Mark Riccio, ... (CT) imaging facility, is using the online crowd-funding ... even 5D imaging to researchers and would-be superheros ... asks "What would YOU do if you had ... to researchers and explorers everywhere, from elementary through ...
(Date:8/22/2014)... 22, 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today ... units of common stock and warrants at a price ... million, prior to deducting underwriting discounts and commissions and ... warrants are immediately separable and will be issued separately.  ... trading on The NASDAQ Stock Market under the ticker ...
Breaking Medicine Technology:MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Cornell's X-ray Imaging Lab Director Uses Kickstarter Campaign to "Democratize" Advanced 3D Imaging 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4
(Date:8/22/2014)... A new study of self-awareness by Kessler ... (MS) may be able to improve their self-awareness ... ahead of print on July 2 in ... Nancy D. Chiaravalloti & John DeLuca: Metacognitive knowledge ... doi: 10.3233/NRE-141113). Self-awareness is one,s ability to recognize ...
(Date:8/22/2014)... Newport Hospital has again attained the distinguished ... Center,s (ANCC) Magnet Recognition Program. Considered the gold ... program recognizes nursing excellence and professionalism. It is ... The unanimous decision to redesignate Newport Hospital was ... national standards of nursing practice. , "It is ...
(Date:8/22/2014)... -- Counseling may do little to help young people ... analyzed 66 studies that included nearly 18,000 people 25 ... for drinking problems. Participants in 49 studies attended a ... of the studies attended group sessions or a mix ... called motivational interviewing was used in the studies. This ...
(Date:8/22/2014)... breakthrough treatments have become available for key subtypes ... these treatments can be pre-identified by looking for ... patients whose lung cancer is driven by rearrangement ... the drug crizotinib, which targets this abnormality. Many ... this success by matching different drugs with specific ...
(Date:8/22/2014)... ItsHot.com, a client-centric manufacturer, wholesaler and ... on its range of beautiful diamond heart pendants. Customers ... Hearts 14K White Rose Gold Diamond Heart Pendant, which ... 77%. Previously priced at $3,715.00, customers can now buy ... of this mesmerizing pendant embedded with 0.66 carats round ...
Breaking Medicine News(10 mins):Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2Health News:Newport Hospital receives nursing's highest credential for third time with Magnet recognition 2Health News:Counseling Does Little to Deter Youth Drinking, Review Finds 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 3Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 4Health News:ItsHot.com Now Offers 60-80% Discount on its Striking Collection of Diamond Heart Pendants 2
... BRIGHTON, Mich., June 30 LifeSecure Insurance Company,(LifeSecure), ... of,Michigan, today announced the executive appointment of Ron ... an accomplished sales executive with extensive knowledge of,the ... LifeSecure, he was,regional sales vice president, long term ...
... Mesothelioma Center as a way for victims, or the ... get help,very honest advice & tailor made assistance at ... According to Americas Watchdog, "watching what happened to a ... help all Mesothelioma victims, with the best possible free ...
... to reduce pain in newborns undergoing painful procedures ... (venipuncture) for the newborn screening test but not ... co-authors. , In this double-blind, randomized controlled ... Hospital, researchers found that "sucrose reduced overall pain ...
... and US guidelines on how much physical activity children need to ... conclude researchers in a study published ahead of print in the ... than half of boys and only one in eight girls manage ... the long term monitoring of 113 boys and 99 girls from ...
... strategies humans use to regulate emotions can determine both ... of New York University and Rutgers University neuroscientists has ... of the journal Nature Neuroscience , shed light ... making. , Previous research has demonstrated these strategies ...
... a revolutionary day in history for anybody who cares about Lung Cancer, ... July 4th, Independence Day, for Lung Cancer. For the first time, in ... Senators Chuck Hagel, Dianne Feinstein and the tireless work over the last ... , ...
Cached Medicine News:Health News:The Mesothelioma Victims Center Offers Victims Of Asbestos Related Cancer & Their Loved Ones The Most Comprehensive Free Service Especially For US Navy Veterans 2Health News:The Mesothelioma Victims Center Offers Victims Of Asbestos Related Cancer & Their Loved Ones The Most Comprehensive Free Service Especially For US Navy Veterans 3Health News:UK and US guidelines on kids' physical activity levels need rethinking 2Health News:NYU, Rutgers study shows how using mental strategies can alter the brain's reward circuitry 2Health News:Senators Chuck Hagel and Dianne Feinstein Make Lung Cancer Matter 2Health News:Senators Chuck Hagel and Dianne Feinstein Make Lung Cancer Matter 3Health News:Senators Chuck Hagel and Dianne Feinstein Make Lung Cancer Matter 4
Straight shafts with heavy Elschnig teeth. Flat serrated handle with slide style lock and polished finished....
Straight shafts with fine Pierse type tips. Flat smooth handle with dull finish....
Straight shafts with delicate 0.7 mm, 1 x 2 teeth. Serrated handle with polished finish....
Straight shafts with 1 x 2 Elsching style teeth. Wide serrated handle with polished finish....
Medicine Products: